Navigation Links
Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy in Bone Cancer Model
Date:11/14/2011

MENLO PARK, Calif., Nov. 14, 2011 /PRNewswire/ -- Virobay, Inc., a privately held biotechnology firm with a broad portfolio of cysteine protease inhibitors for the treatment of autoimmune diseases, neuropathic pain, liver diseases and cancer, presented data showing that one of the company's spectrum-selective cathepsin inhibitors demonstrated efficacy in a mouse model of bone cancer pain.  Virobay has a series of advanced, spectrum-selective cathepsin inhibitors with structural diversity and demonstrated activity in bone cancer and related pain.  VBY-825, a prototype compound within this series, is an orally bioavailable, highly potent, reversible inhibitor of a subset of cathepsin proteases (including cathepsins S, K, L and B) that demonstrated protection from bone destruction and remodeling in this metastatic breast cancer model, as well as significant analgesic activity.  These preclinical data suggest that Virobay's spectrum-selective cathepsin inhibitors have potential therapeutic utility in the treatment of metastatic and primary bone cancer and cancer-related bone pain, with a mechanism of action that would be highly complementary to standard chemotherapy.

The data were presented in a poster, titled "Efficacy of a Spectrum-Selective Cathepsin Inhibitor in a Mouse Model of Bone Cancer," by Holsinger, et al., at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, on Sunday, November 13th.

"These preclinical data provide a compelling demonstration of the therapeutic potential of Virobay's cathepsin inhibitors in bone cancer and bone cancer pain," said Robert Booth, PhD, Virobay's president and chief executive officer.  "The data demonstrate that the anti-tumorigenic and analgesic activity is due to the selective targeting of specific cathepsins that are known to facilitate osteolytic metastasis, bone invasion and bone matrix degradation.  We believe that these dat
'/>"/>

SOURCE Virobay, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
2. Study Shows C1-Esterase Inhibitor Concentrate is Safe and Consistently Effective for Long-Term Treatment of Hereditary Angioedema Attacks at Any Body Location
3. Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for Cancer
4. ViiV Healthcare Starts Phase III Clinical Programme of Celsentri/Selzentry® (maraviroc) versus Truvada® (tenofovir + FTC), in combination with a Protease Inhibitor in people living with HIV
5. Enantas Lead NS5A Inhibitor Candidate for HCV, EDP-239, Selected as One of Windhovers Top 10 Infectious Disease Projects to Watch
6. Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T
7. Modulation of inhibitory output is key function of antiobesity hormone
8. Neurocrine Biosciences Announces Notice of Allowance for Composition of Matter Patent on VMAT2 Inhibitor
9. Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis
10. Ardea Biosciences Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at 2011 American Society of Clinical Oncology Annual Meeting
11. Pharmacyclics Achieves $7 Million Development Milestone for HDAC Inhibitor, PCI-24781 / S 78454 with Servier
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... -- MiMedx Group, Inc. (NASDAQ: MDXG ), ... protected regenerative biomaterials and bioimplants processed from human ... clinical study.    The study article, ... Trial Evaluating the Use of Dehydrated ... Therapy vs. Multi-layer Compression Therapy Alone in the ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Immunomic Therapeutics, ... Innovation Research (SBIR) grant to support the continued preclinical ... provide ITI with approximately $255,000 over one year to ... cause of food allergy, affect over one million Americans ... peanut allergy. Tree nut exposure is also a risk ...
(Date:9/17/2014)... , Sept. 17, 2014 Alternative Fuels Americas, ... to form a Special Purpose Vehicle in partnership with Jatro ... centric agro energy company. The SPV shall be called AFAI ... with AFAI as majority shareholder. The SPV shall pursue Jatropha ... , particularly Ethiopia . ...
(Date:9/17/2014)... FOREST, California , 17 de septiembre ... CYRX) ("la compañía"), principal proveedor mundial de ... de las ciencias de la vida, anunció ... compañía de logística global con sede en ... su base de clientes Europa en rápido ...
Breaking Biology Technology:MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 3MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 4Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 3AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 2AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 2Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 4Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 5
... Compendia Bioscience, Inc.,today announced the release and ... high-value product extension of Oncomine,Research Edition for ... includes custom gene filters, integration with Ingenuity,Pathway ... Concepts Map,including the ability to upload custom ...
... Offer Full Range of Fertility Services and ... Dr. John Jain, a,fertility specialist with ... the,country, announced today the grand opening of ... reproductive health center in Santa,Monica, California. The ...
... Features ... Renowned Investment Banker and Biotechnology Company Start-up Leader ... Stelios Papadopoulos, PhD Provides Keynote Address, BOSTON, ... Opportunities Investor Conference, New,England,s largest biotechnology investor forum, will ...
Cached Biology Technology:Compendia Bioscience Announces the Release and Availability of Oncomine(TM) Research Premium Edition 2Pioneer in Reproductive Medicine Opens The Country's First Comprehensive Fertility Practice 22007 Massachusetts Biotechnology Council MASS Opportunities Investment Conference Showcases Leading Growth Companies 22007 Massachusetts Biotechnology Council MASS Opportunities Investment Conference Showcases Leading Growth Companies 3
(Date:9/17/2014)... from the Copenhagen Centre for Social Evolution and Yale ... that birth weight and -length can partially predict the ... as autism and schizophrenia later in life. The study ... subsequent hospital diagnoses for up to 30 years, and ... study is published today in the Proceedings of ...
(Date:9/17/2014)... Biomedical Research Institute (ICO-IDIBELL), led by David Garcia-Mollev ... accompanying cells in colorectal tumors. Analysis of these ... predict the evolution of the patient and thus ... Biomarkers , Colorectal cancer is ... sexes. About 30,000 new cases are diagnosed each ...
(Date:9/17/2014)... DC A team of researchers working on a Carnegie ... coral growth rates have plummeted 40% since the mid-1970s. ... an important role in this perilous slowdown. , ... facing coral reefs, the team compared current measurements of ... Barrier Reef with similar measurements taken more than 30 ...
Breaking Biology News(10 mins):Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3Five genes to predict colorectal cancer relapses 2Coral growth rate plummets in 30-year comparison 2
... Technology (Caltech) have devised a new techniqueusing a sheet ... of molecules. The technique, which was used to obtain ... at room temperature, can also be used to image ... and other biomolecules. A paper describing the method ...
... prototype model of the first implantable artificial kidney, in ... for dialysis. The device, which would include thousands ... mimic the metabolic and water-balancing roles of a real ... engineers, biologists and physicians nationwide, led by Shuvo Roy, ...
... is a joke no more. In a special September issue ... ( CBE-LSE ), the adage that biology is for science ... "Bio-math" or "math-bio" is in the future for students of ... research articles on new ways to integrate mathematical thinking into ...
Cached Biology News:Caltech chemists develop simple technique to visualize atomic-scale structures 2Caltech chemists develop simple technique to visualize atomic-scale structures 3UCSF unveils model for implantable artificial kidney to replace dialysis 2UCSF unveils model for implantable artificial kidney to replace dialysis 3You say, 'bio-math,' I say, 'math-bio': Crossing science education divide 2
Amino Acid Analysis is performed using ion-exchange separation of the amino acids from acid hydrolysates, followed by ninhydrin detection. Typical quantities required are 0.1 to 0.5 mg, depending on...
ANTI CORTIS BIN GLOB...
ANTI S. ENTERID LPS...
... This DuoSet ELISA Development kit contains ... of sandwich ELISAs to measure natural and ... and serum. Each kit contains sufficient ... 96-well plates, provided that the following conditions ...
Biology Products: